Tag: Bipolar Mania
-
J&J’s CAPLYTA Meets Phase 3 Trial Goal in Bipolar Mania
Johnson & Johnson’s CAPLYTA met the primary endpoint in Phase 3 Study 451, producing a 4.8-point greater reduction in manic symptoms versus placebo and significant improvement from Day 3. Results from the second pivotal study remain under analysis.
-
CAPLYTA Mechanism in Bipolar Mania: Dual D2 Modulation
CAPLYTA’s exact therapeutic mechanism remains unresolved, but its proposed pharmacology combines strong serotonin 5-HT2A antagonism with distinct presynaptic and postsynaptic dopamine D2 effects. This BP Science analysis examines how that profile may regulate dopamine signaling and differ from competing antipsychotics.